{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:37:29Z","timestamp":1794613049384,"version":"4.9.1"},"reference-count":88,"publisher":"American Association for Cancer Research (AACR)","issue":"1","funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["Rama Guntupalli Endowment for Leukemia Research"],"award-info":[{"award-number":["Rama Guntupalli Endowment for Leukemia Research"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Incorporation of the B-cell lymphoma 2 inhibitor venetoclax into the treatment of acute myeloid leukemia (AML) has been transformative. Initially studied in combination with low-intensity therapy in older adults and those ineligible for intensive therapy, venetoclax has proven to be efficacious and tolerable in this setting. Recently, venetoclax has been investigated in combination with more intensive regimens. However, these approaches come with a myriad of dosing strategies and questions surrounding the practicality of venetoclax administration. In this study, we provide an overview of the incorporation of venetoclax into AML treatment and a discussion of practical considerations and areas of unmet need.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In recent years, there has been tremendous interest surrounding the integration of venetoclax into both non-intensive and intensive chemotherapy regimens for AML. However, with this increasing utilization of venetoclax, considerable questions surrounding key issues such as dosing strategies and the practicality of venetoclax administration have arisen. This review highlights the evolution of venetoclax-based regimens in AML and provides a commentary on notable practical considerations when utilizing this agent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-24-0171","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T09:39:35Z","timestamp":1732095575000},"page":"23-37","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1945-2571","authenticated-orcid":false,"given":"Hannah","family":"Goulart","sequence":"first","affiliation":[{"name":"1Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4166-5717","authenticated-orcid":false,"given":"Caitlin R.","family":"Rausch","sequence":"additional","affiliation":[{"name":"3Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"2026041310203844200_bib1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2026041310203844200_bib2","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s11912-023-01450-0","article-title":"Approach to the older patient with acute myeloid leukemia","volume":"25","author":"Zimmer","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"2026041310203844200_bib3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"2026041310203844200_bib4","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026041310203844200_bib5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fonc.2018.00636","article-title":"Targeting the Bcl-2 family in B cell lymphoma","volume":"8","author":"Adams","year":"2018","journal-title":"Front Oncol"},{"key":"2026041310203844200_bib6","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","article-title":"High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"81","author":"Campos","year":"1993","journal-title":"Blood"},{"key":"2026041310203844200_bib7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"key":"2026041310203844200_bib8","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.leu.2402434","article-title":"The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia","volume":"16","author":"Karakas","year":"2002","journal-title":"Leukemia"},{"key":"2026041310203844200_bib9","doi-asserted-by":"crossref","first-page":"666","DOI":"10.4149\/neo_2013_085","article-title":"Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3","volume":"60","author":"Mehta","year":"2013","journal-title":"Neoplasma"},{"key":"2026041310203844200_bib10","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/sj.leu.2401573","article-title":"Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid","volume":"13","author":"Andreeff","year":"1999","journal-title":"Leukemia"},{"key":"2026041310203844200_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"2026041310203844200_bib12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"2026041310203844200_bib13","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"key":"2026041310203844200_bib14","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026041310203844200_bib15","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/10428194.2014.910657","article-title":"Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies","volume":"56","author":"Bogenberger","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2026041310203844200_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2026041310203844200_bib17","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann Hematol"},{"key":"2026041310203844200_bib18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"2026041310203844200_bib19","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"2026041310203844200_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"2026041310203844200_bib21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"key":"2026041310203844200_bib22","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia","volume":"28","author":"Cashen","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026041310203844200_bib23","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"key":"2026041310203844200_bib24","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"key":"2026041310203844200_bib25","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer"},{"key":"2026041310203844200_bib26","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026041310203844200_bib27","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"L\u00f6wenberg","year":"2009","journal-title":"N Engl J Med"},{"key":"2026041310203844200_bib28","first-page":"169","article-title":"Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia","volume":"1","author":"Gandhi","year":"1995","journal-title":"Clin Cancer Res"},{"key":"2026041310203844200_bib29","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V87.1.256.256","article-title":"Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions","volume":"87","author":"Gandhi","year":"1996","journal-title":"Blood"},{"key":"2026041310203844200_bib30","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/S2352-3026(18)30132-7","article-title":"Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial","volume":"5","author":"Kadia","year":"2018","journal-title":"Lancet Haematol"},{"key":"2026041310203844200_bib31","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.21.02823","article-title":"Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia","volume":"40","author":"Kadia","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026041310203844200_bib32","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood-2023-182250","article-title":"Cladribine with low dose cytarabine and venetoclax alternated with azacytidine and venetoclax for acute myeloid leukemia: prognostic analysis of a phase 2 clinical trial","volume":"142","author":"Bataller","year":"2023","journal-title":"Blood"},{"key":"2026041310203844200_bib33","doi-asserted-by":"crossref","first-page":"7047","DOI":"10.1200\/JCO.2023.41.16_suppl.7047","article-title":"Superior outcomes after allogeneic stem cell transplantation (SCT) among patients (Pts) \u2265 60 years (yrs) treated with cladribine (CLAD), low dose cytarabine (LDAC) plus venetoclax (Ven) for newly diagnosed acute myeloid leukemia (AML)","volume":"41","author":"Senapati","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026041310203844200_bib34","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"2026041310203844200_bib35","doi-asserted-by":"crossref","first-page":"e8385270","DOI":"10.1097\/01.HS9.0000967440.83852.70","article-title":"S132: updated results of VEN-A-QUI study: a phase 1 to 2 trial to assess the safety and efficacy of triplets for newly diagnosed unfit AML patients: azacitidine or low-dose cytarabine with venetoclax and quizartinib","volume":"7","author":"Miguel Bergua Burgues","year":"2023","journal-title":"Hemasphere"},{"key":"2026041310203844200_bib36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood-2023-186699","article-title":"Phase I\/II study of quizartinib, venetoclax, and decitabine triple combination in FLT3-ITD mutated AML","volume":"142","author":"Yilmaz","year":"2023","journal-title":"Blood"},{"key":"2026041310203844200_bib37","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A phase Ib\/II study of ivosidenib with venetoclax \u00b1 azacitidine in IDH1-mutated myeloid malignancies","volume":"4","author":"Lachowiez","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"2026041310203844200_bib38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-021-00604-2","article-title":"Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy","volume":"12","author":"Venugopal","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026041310203844200_bib39","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026041310203844200_bib40","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"key":"2026041310203844200_bib41","doi-asserted-by":"crossref","first-page":"E29","DOI":"10.1002\/ajh.23884","article-title":"Comparison of 60 or 90 mg\/m2 of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics","volume":"90","author":"Devillier","year":"2015","journal-title":"Am J Hematol"},{"key":"2026041310203844200_bib42","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2017.72.8618","article-title":"Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026041310203844200_bib43","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026041310203844200_bib44","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"2026041310203844200_bib45","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1182\/blood-2023-182969","article-title":"Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed, high risk acute myeloid leukemia","volume":"142","author":"Jen","year":"2023","journal-title":"Blood"},{"key":"2026041310203844200_bib46","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am J Hematol"},{"key":"2026041310203844200_bib47","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2011.37.1286","article-title":"Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study","volume":"30","author":"Holowiecki","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026041310203844200_bib48","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/ajh.27054","article-title":"Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia","volume":"98","author":"Kadia","year":"2023","journal-title":"Am J Hematol"},{"key":"2026041310203844200_bib49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2013.51.8571","article-title":"High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial","volume":"32","author":"Willemze","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026041310203844200_bib50","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol"},{"key":"2026041310203844200_bib51","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1016\/S2352-3026(22)00076-X","article-title":"Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study","volume":"9","author":"Lachowiez","year":"2022","journal-title":"Lancet Haematol"},{"key":"2026041310203844200_bib52","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026041310203844200_bib53","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.1002\/ajh.27180","article-title":"Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: comparative analysis of response, toxicity, and survival","volume":"99","author":"Karrar","year":"2024","journal-title":"Am J Hematol"},{"key":"2026041310203844200_bib54","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2022-165464","article-title":"Reduced venetoclax exposition to seven days of azacitidine is efficient in treatment-na\u00efve patients with acute myeloid leukemia","volume":"140","author":"Willekens","year":"2022","journal-title":"Blood"},{"key":"2026041310203844200_bib55","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1182\/blood-2023-185437","article-title":"Acute myeloid leukemia patients who stopped venetoclax or\/and azacytidine for other reasons than progression have a prolonged treatment free remission and overall survival. A filo study","volume":"142","author":"Garciaz","year":"2023","journal-title":"Blood"},{"key":"2026041310203844200_bib56","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026041310203844200_bib57","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","article-title":"Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia","volume":"6","author":"Chua","year":"2022","journal-title":"Blood Adv"},{"key":"2026041310203844200_bib58","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica"},{"key":"2026041310203844200_bib59","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov"},{"key":"2026041310203844200_bib60","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci Rep"},{"key":"2026041310203844200_bib61","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41375-019-0485-x","article-title":"Genetic characterization of ABT-199 sensitivity in human AML","volume":"34","author":"Bisaillon","year":"2020","journal-title":"Leukemia"},{"key":"2026041310203844200_bib62","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat Cancer"},{"key":"2026041310203844200_bib63","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1038\/bcj.2012.5","article-title":"Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies","volume":"2","author":"Kasper","year":"2012","journal-title":"Blood Cancer J"},{"key":"2026041310203844200_bib64","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Singh Mali","year":"2021","journal-title":"Haematologica"},{"key":"2026041310203844200_bib65","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","article-title":"FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation","volume":"114","author":"Yoshimoto","year":"2009","journal-title":"Blood"},{"key":"2026041310203844200_bib66","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ajh.25146","article-title":"Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am J Hematol"},{"key":"2026041310203844200_bib67","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","article-title":"FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation","volume":"6","author":"Zhu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026041310203844200_bib68","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2020","journal-title":"Haematologica"},{"key":"2026041310203844200_bib69","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"key":"2026041310203844200_bib70","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.3324\/haematol.2021.280487","article-title":"Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases","volume":"107","author":"Fang","year":"2022","journal-title":"Haematologica"},{"key":"2026041310203844200_bib71","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","article-title":"Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"3","author":"Aldoss","year":"2019","journal-title":"Blood Adv"},{"key":"2026041310203844200_bib72","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.3390\/cancers13246285","article-title":"Infections of venetoclax-based chemotherapy in acute myeloid leukemia: rationale for proper antimicrobial prophylaxis","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026041310203844200_bib73","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1080\/10428194.2022.2047964","article-title":"Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax","volume":"63","author":"Chen","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"2026041310203844200_bib74","doi-asserted-by":"crossref","first-page":"1012334","DOI":"10.3389\/fcimb.2022.1012334","article-title":"High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia","volume":"12","author":"Wang","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"2026041310203844200_bib75","doi-asserted-by":"crossref","first-page":"e710","DOI":"10.1016\/S2352-3026(23)00155-2","article-title":"Understanding the barriers to AML care in India","volume":"10","author":"Senapati","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026041310203844200_bib76","first-page":"290","article-title":"Hypomethylating agents+venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy\u2014novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country","volume":"11","author":"Mirgh","year":"2021","journal-title":"Am J Blood Res"},{"key":"2026041310203844200_bib77","doi-asserted-by":"crossref","first-page":"107341","DOI":"10.1016\/j.leukres.2023.107341","article-title":"Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis?","volume":"131","author":"Guarana","year":"2023","journal-title":"Leuk Res"},{"key":"2026041310203844200_bib78","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/PPO.0000000000000567","article-title":"How we incorporate venetoclax in treatment regimens for acute myeloid leukemia","volume":"28","author":"Maiti","year":"2022","journal-title":"Cancer J"},{"key":"2026041310203844200_bib79","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Ther"},{"key":"2026041310203844200_bib80","unstructured":"Venclexta prescribing information. [cited 2024 Sep 19]. Available from:https:\/\/www.rxabbvie.com\/pdf\/venclexta.pdf."},{"key":"2026041310203844200_bib81","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1182\/blood-2023-180491","article-title":"Prospective pharmacokinetic evaluation of venetoclax (VEN) in AML demonstrates significant and variable drug interactions with azole antifungals that increase ven exposure, reduce clearance, and necessitate re-evaluation of dose adjustments","volume":"142","author":"Kawedia","year":"2023","journal-title":"Blood"},{"key":"2026041310203844200_bib82","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"2026041310203844200_bib83","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/bloodadvances.2022009010","article-title":"Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia","volume":"7","author":"Lachowiez","year":"2023","journal-title":"Blood Adv"},{"key":"2026041310203844200_bib84","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"key":"2026041310203844200_bib85","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/bloodadvances.2021005585","article-title":"European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol","volume":"6","author":"Bataller","year":"2022","journal-title":"Blood Adv"},{"key":"2026041310203844200_bib86","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood-2022-169509","article-title":"ELN risk stratification is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"2026041310203844200_bib87","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","article-title":"Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv"},{"key":"2026041310203844200_bib88","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood.2023020649","article-title":"Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia","volume":"142","author":"Senapati","year":"2023","journal-title":"Blood"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0171\/3518910\/bcd-24-0171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/1\/23\/3530181\/bcd-24-0171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/1\/23\/3530181\/bcd-24-0171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:20:56Z","timestamp":1776090056000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/1\/23\/750802\/Venetoclax-Based-Combination-Regimens-in-Acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,11,20]]},"published-print":{"date-parts":[[2025,1,8]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-24-0171","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]}}}